Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Brain Neoplasms 635Glioblastoma 566Glioma 405Neuroblastoma 174Neoplasms 123Astrocytoma 106Central Nervous System Neoplasms 103Medulloblastoma 87Breast Neoplasms 86Meningioma 82Carcinoma, Non-Small-Cell Lung 78Melanoma 77Lung Neoplasms 69Sarcoma 66Ependymoma 64Neurofibromatosis 1 63Recurrence 50Oligodendroglioma 48Neoplasm Metastasis 48Osteosarcoma 47Meningeal Carcinomatosis 46Rhabdomyosarcoma 45Diffuse Intrinsic Pontine Glioma 44Pheochromocytoma 43Rhabdoid Tumor 41Paraganglioma 41Gliosarcoma 40Sarcoma, Ewing 39Pancreatic Neoplasms 39Colorectal Neoplasms 33

Interventions

XENP 1595 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurocognitive Disorders × CNS × 1 year × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05984667 2026-02-20

C-SMART

Virginia Commonwealth University

Completed
32 enrolled
CNS

Brain Neoplasms, Glioma, Neurocognitive Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡